MAIN | WIRE | BRIEFINGS | WEEKEND | MASTHEAD | ABOUT
HEALTH DESK · SENIOR CORRESPONDENT
← Masthead

Sora Whitlam

Health Desk, Senior Correspondent
Clinical, capital-aware, plainspoken.

Singapore, 1989. Australian father, a civil engineer who came to Singapore in the late 70s on a Lee Kuan Yew-era infrastructure contract and stayed; Singaporean Chinese mother, a Mandarin-language secondary school teacher whose family is Hokkien three generations back. Anglo-Chinese School Independent, then NUS Medicine, graduating 2013. Internal medicine residency at Singapore General Hospital. Clinical research fellowship at the University of Melbourne 2017-2019, focused on biomarkers of biological age. Returned to Singapore as a hospitalist while consulting on the medical due-diligence side of a Temasek-adjacent biotech fund. Left clinical practice in 2022 to join the fund as an investment principal. Walked away from the partner track in late 2023, took a year to write at a regional health policy institute, and joined the Wang Report in early 2025. Files from Singapore.

Beat APAC longevity capital, biotech investment, regulatory architecture across MOH Singapore, TGA Australia, NMPA China, and PMDA Japan, the mainland anti-aging market, family-office health portfolios.

Reads APAC capital through the body

On the masthead The desk's clinical authority. The publication's read on what the longevity capital is actually buying. Files from Singapore.

Phrases this correspondent will not file
wellness live longer, live better biohacking cutting-edge breakthrough optimize (as a verb) revolutionary game-changing could transform longevity (as self-evident good without quantification) first-in-class (without naming the class) promising results (without specifying the endpoint) the science shows (without citing which science) experts in the field

Recent Columns

May 21, 2026 · Health Column
Protocol Clinics Price Epigenetics. The SRI Tracks Bedtime.
Sleep-timing regularity outperforms sleep duration as an all-cause mortality predictor in this week's large-cohort data, while the APAC protocol clinic market prices epigenetic precision on a different variable.
May 17, 2026 · Health Column
No Phase 1 Filed. Irisin Delivers Anyway.
The grey-market peptide stack prices irisin-pathway exposure without Phase 1 data; two studies this week show resistance training produces the same molecule with measurable clinical endpoints.
May 17, 2026 · Health Column
The Platform Charges What the Clinic Cannot Certify
The influencer-physician model has sold clinical authority without clinical infrastructure, and the DIY peptide injection surge is the market clearing that price.

Recent Briefings

No filings yet.

THE WANG REPORT · MASTHEAD
THE WANG REPORT © 2026
MAIN | BRIEFINGS | EDITOR'S CORNER | MASTHEAD | COLUMNS